Aclarion (NASDAQ:ACON) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Aclarion (NASDAQ:ACON) from a sell rating to a hold rating in a report published on Sunday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Aclarion has an average rating of “Sell”.

Aclarion Trading Down 0.8%

Shares of ACON opened at $2.54 on Friday. Aclarion has a 12-month low of $2.34 and a 12-month high of $229.50. The stock has a market cap of $2.16 million, a P/E ratio of -0.17 and a beta of 1.44. The company has a 50-day moving average of $4.20 and a two-hundred day moving average of $6.23.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.